FSD Pharma Files Year-End Results
Ticker: QNTM · Form: 6-K · Filed: Apr 16, 2024 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Fsd Pharma Inc. (QNTM) |
| Form Type | 6-K |
| Filed Date | Apr 16, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, filing, year-end
TL;DR
FSD Pharma dropped its year-end financials, check the 6-K.
AI Summary
FSD Pharma Inc. filed a Form 6-K on March 29, 2024, reporting on its activities for March 2024. The filing includes a press release announcing the company's year-end financial results. Nathan Coyle, Chief Financial Officer, signed the report.
Why It Matters
This filing provides investors with the company's year-end financial performance, which is crucial for assessing its current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing of financial results and does not introduce new risks.
Key Players & Entities
- FSD Pharma Inc. (company) — Registrant
- Nathan Coyle (person) — Chief Financial Officer
- March 29, 2024 (date) — Filing date
- March 2024 (date) — Reporting period
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report on FSD Pharma Inc.'s activities for the month of March 2024, including the announcement of its year-end financial results via an attached press release.
Who signed the Form 6-K on behalf of FSD Pharma Inc.?
Nathan Coyle, Chief Financial Officer, signed the Form 6-K on behalf of FSD Pharma Inc.
What is the Commission File Number for FSD Pharma Inc.?
The Commission File Number for FSD Pharma Inc. is 001-39152.
Which exhibit is attached to this Form 6-K?
Exhibit 99.1, a Press Release, is attached to this Form 6-K.
What is FSD Pharma Inc.'s principal executive office address?
FSD Pharma Inc.'s principal executive office is located at 199 Bay St., Suite 4000, Toronto, Ontario M5L 1A9, Canada.
Filing Stats: 146 words · 1 min read · ~1 pages · Grade level 9.7 · Accepted 2024-04-15 18:48:33
Filing Documents
- fsd_6k.htm (6-K) — 9KB
- fsd_ex991.htm (EX-99.1) — 13KB
- fsd_ex991img6.jpg (GRAPHIC) — 6KB
- 0001654954-24-004643.txt ( ) — 32KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. FSD Pharma Inc. (Registrant) Date: March 29, 2024 By: /s/ Nathan Coyle Nathan Coyle, Chief Financial Officer 2 EXHIBIT INDEX Exhibit Description 99.1 Press Release 3